

# Ichiro Nakano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2833732/publications.pdf>

Version: 2024-02-01

173  
papers

13,515  
citations

23567

58  
h-index

24258

110  
g-index

187  
all docs

187  
docs citations

187  
times ranked

19496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancerous stem cells can arise from pediatric brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15178-15183.	7.1	1,686
2	Mesenchymal Differentiation Mediated by NF- $\kappa$ B Promotes Radiation Resistance in Glioblastoma. Cancer Cell, 2013, 24, 331-346.	16.8	856
3	Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Cell, 2013, 23, 839-852.	16.8	665
4	Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8644-8649.	7.1	523
5	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Science Advances, 2018, 4, eaar2766.	10.3	416
6	Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nature Neuroscience, 2013, 16, 1373-1382.	14.8	408
7	miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development. PLoS ONE, 2013, 8, e78115.	2.5	270
8	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Scientific Reports, 2015, 5, 11483.	3.3	270
9	The AMPK Inhibitor Compound C Is a Potent AMPK-Independent Antiglioma Agent. Molecular Cancer Therapeutics, 2014, 13, 596-605.	4.1	229
10	Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma Via Intercellular Transfer of Splicing Factors. Cancer Cell, 2018, 34, 119-135.e10.	16.8	222
11	Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1 $\alpha$ -Mediated Lipogenesis. Clinical Cancer Research, 2016, 22, 5337-5348.	7.0	210
12	Extracellular Vesicles Modulate the Glioblastoma Microenvironment via a Tumor Suppression Signaling Network Directed by miR-1. Cancer Research, 2014, 74, 738-750.	0.9	197
13	Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. Stem Cells, 2016, 34, 2026-2039.	3.2	189
14	MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. Cancer Cell, 2017, 32, 840-855.e8.	16.8	188
15	MELK-Dependent FOXM1 Phosphorylation is Essential for Proliferation of Glioma Stem Cells. Stem Cells, 2013, 31, 1051-1063.	3.2	166
16	Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation. Cell Reports, 2019, 26, 1893-1905.e7.	6.4	161
17	EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner. Stem Cell Reports, 2015, 4, 226-238.	4.8	159
18	The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches. Cell Reports, 2016, 15, 2500-2509.	6.4	156

#	ARTICLE	IF	CITATIONS
19	Laminin alpha 2 enables glioblastoma stem cell growth. <i>Annals of Neurology</i> , 2012, 72, 766-778.	5.3	151
20	Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF- $\kappa$ B-dependent Manner. <i>Cancer Cell</i> , 2016, 29, 201-213.	16.8	147
21	Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. <i>Journal of Neuroscience Research</i> , 2008, 86, 48-60.	2.9	144
22	Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. <i>Journal of Cell Biology</i> , 2005, 170, 413-427.	5.2	136
23	Relationship between the tautomeric structures of curcumin derivatives and their $\text{A}\beta$ -binding activities in the context of therapies for Alzheimer's disease. <i>Biomaterials</i> , 2010, 31, 4179-4185.	11.4	133
24	miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2015, 123, 205-216.	2.9	128
25	Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 3002-3013.	0.9	122
26	FOXD1 $\kappa$ ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells. <i>Cancer Research</i> , 2016, 76, 7219-7230.	0.9	120
27	CD44v6 Regulates Growth of Brain Tumor Stem Cells Partially through the AKT-Mediated Pathway. <i>PLoS ONE</i> , 2011, 6, e24217.	2.5	115
28	Tumor-Specific Activation of the C-JUN/MELK Pathway Regulates Glioma Stem Cell Growth in a p53-Dependent Manner. <i>Stem Cells</i> , 2013, 31, 870-881.	3.2	111
29	Phenotypic and functional heterogeneity of GFAP-expressing cells in vitro: Differential expression of LeX/CD15 by GFAP-expressing multipotent neural stem cells and non-neurogenic astrocytes. <i>Glia</i> , 2006, 53, 277-293.	4.9	109
30	IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. <i>Nature Cell Biology</i> , 2019, 21, 1003-1014.	10.3	107
31	AMP kinase promotes glioblastoma bioenergetics and tumour growth. <i>Nature Cell Biology</i> , 2018, 20, 823-835.	10.3	106
32	Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, <i>c-Myb</i> . <i>Clinical Cancer Research</i> , 2012, 18, 1268-1280.	7.0	105
33	MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. <i>Neuro-Oncology</i> , 2013, 15, 1212-1224.	1.2	104
34	Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. <i>Neuro-Oncology</i> , 2018, 20, 236-248.	1.2	103
35	<i>MIR93</i> ( <i>microRNA -93</i> ) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy. <i>Autophagy</i> , 2019, 15, 1100-1111.	9.1	100
36	MELK "a conserved kinase: functions, signaling, cancer, and controversy. <i>Clinical and Translational Medicine</i> , 2015, 4, 11.	4.0	99

#	ARTICLE	IF	CITATIONS
37	Extracellular vesicles in the biology of brain tumour stem cells – Implications for inter-cellular communication, therapy and biomarker development. <i>Seminars in Cell and Developmental Biology</i> , 2015, 40, 17-26.	5.0	86
38	Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. <i>Journal of Clinical Investigation</i> , 2017, 127, 3075-3089.	8.2	86
39	Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. <i>Cancer Research</i> , 2016, 76, 2876-2881.	0.9	85
40	Patterns of Jagged1, Jagged2, Delta-like 1 and Delta-like 3 expression during late embryonic and postnatal brain development suggest multiple functional roles in progenitors and differentiated cells. <i>Journal of Neuroscience Research</i> , 2004, 75, 330-343.	2.9	83
41	EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. <i>Journal of Clinical Investigation</i> , 2014, 124, 3741-3756.	8.2	82
42	Stem cell signature in glioblastoma: therapeutic development for a moving target. <i>Journal of Neurosurgery</i> , 2015, 122, 324-330.	1.6	81
43	A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1818-1828.	4.1	80
44	Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin-Ran Protein Complex. <i>Clinical Cancer Research</i> , 2013, 19, 631-642.	7.0	80
45	Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. <i>Nature Communications</i> , 2020, 11, 4660.	12.8	80
46	RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. <i>Oncotarget</i> , 2015, 6, 14766-14776.	1.8	78
47	Crosstalk between Glioma-Initiating Cells and Endothelial Cells Drives Tumor Progression. <i>Cancer Research</i> , 2014, 74, 4482-4492.	0.9	77
48	High-Throughput Flow Cytometry Screening Reveals a Role for Junctional Adhesion Molecule A as a Cancer Stem Cell Maintenance Factor. <i>Cell Reports</i> , 2014, 6, 117-129.	6.4	76
49	Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. <i>Clinical Cancer Research</i> , 2017, 23, 6958-6968.	7.0	74
50	A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. <i>Nature Communications</i> , 2016, 7, 12885.	12.8	72
51	Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBP $\beta$ Signaling. <i>Cancer Research</i> , 2017, 77, 4973-4984.	0.9	68
52	Enhanced fatty acid oxidation provides glioblastoma cells metabolic plasticity to accommodate to its dynamic nutrient microenvironment. <i>Cell Death and Disease</i> , 2020, 11, 253.	6.3	67
53	Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth. <i>Cell Reports</i> , 2016, 16, 1527-1535.	6.4	66
54	Brain Tumor Stem Cells. <i>Pediatric Research</i> , 2006, 59, 54R-58R.	2.3	63

#	ARTICLE	IF	CITATIONS
55	Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. <i>Neuro-Oncology</i> , 2011, 13, 622-634.	1.2	63
56	SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes. <i>Cancer Research</i> , 2019, 79, 5288-5301.	0.9	63
57	Neural progenitor genes. <i>Developmental Biology</i> , 2003, 264, 309-322.	2.0	62
58	Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 839-846.	1.6	62
59	Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4055-64.	7.1	60
60	Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling. <i>Cancer Letters</i> , 2014, 353, 194-200.	7.2	58
61	MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. <i>Stem Cell Reports</i> , 2017, 8, 1497-1505.	4.8	58
62	Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. <i>Journal of Clinical Investigation</i> , 2015, 125, 4269-4280.	8.2	57
63	Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells. <i>PLoS Biology</i> , 2015, 13, e1002152.	5.6	56
64	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. <i>Cell Reports</i> , 2017, 21, 2183-2197.	6.4	56
65	Maternal Embryonic Leucine Zipper Kinase: Key Kinase for Stem Cell Phenotype in Glioma and Other Cancers. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1393-1398.	4.1	55
66	PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. <i>Molecular Cell</i> , 2021, 81, 1276-1291.e9.	9.7	54
67	Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. <i>Neuro-Oncology</i> , 2018, 20, 192-202.	1.2	52
68	Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. <i>World Neurosurgery</i> , 2019, 129, 90-100.	1.3	52
69	A streamlined protocol for the use of the semi-sitting position in neurosurgery: A report on 48 consecutive procedures. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 32-34.	1.5	51
70	Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. <i>Neuro-Oncology</i> , 2014, 16, 1354-1364.	1.2	51
71	An Update on Neurofibromatosis Type 1-Associated Gliomas. <i>Cancers</i> , 2020, 12, 114.	3.7	50
72	Stem Cell-derived Neural Stem/Progenitor Cell Supporting Factor Is an Autocrine/Paracrine Survival Factor for Adult Neural Stem/Progenitor Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 35491-35500.	3.4	47

#	ARTICLE	IF	CITATIONS
73	Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like Cells. <i>Stem Cell Reports</i> , 2015, 4, 899-913.	4.8	47
74	Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 4360-4369.	0.9	46
75	On-Chip Clonal Analysis of Glioma-Stem-Cell Motility and Therapy Resistance. <i>Nano Letters</i> , 2016, 16, 5326-5332.	9.1	44
76	Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications. <i>Journal of Neurosurgery</i> , 2020, 133, 655-663.	1.6	44
77	Detoxification of oxidative stress in glioma stem cells: Mechanism, clinical relevance, and therapeutic development. <i>Journal of Neuroscience Research</i> , 2014, 92, 1419-1424.	2.9	43
78	N-cadherin upregulation mediates adaptive radioresistance in glioblastoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	43
79	Suppression of Peroxiredoxin 4 in Glioblastoma Cells Increases Apoptosis and Reduces Tumor Growth. <i>PLoS ONE</i> , 2012, 7, e42818.	2.5	42
80	Choroid Plexus Papilloma in the Posterior Third Ventricle: Case Report. <i>Neurosurgery</i> , 1997, 40, 1279-1282.	1.1	41
81	SIRT1 is required for oncogenic transformation of neural stem cells and for the survival of cancer cells with neural stemness in a p53-dependent manner. <i>Neuro-Oncology</i> , 2015, 17, 95-106.	1.2	40
82	Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole. <i>Scientific Reports</i> , 2017, 7, 3605.	3.3	40
83	Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 2574-2584.	7.0	40
84	ICOSLG-mediated regulatory T cell expansion and IL-10 production promote progression of glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 333-344.	1.2	40
85	CDK4/6 inhibition is more active against the glioblastoma proneural subtype. <i>Oncotarget</i> , 2017, 8, 55319-55331.	1.8	39
86	MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. <i>Molecular Cancer Research</i> , 2016, 14, 984-993.	3.4	38
87	miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC. <i>Nature Communications</i> , 2018, 9, 5110.	12.8	38
88	Imidazo[1,2- <i>a</i> ]pyridine Derivatives as Aldehyde Dehydrogenase Inhibitors: Novel Chemotypes to Target Glioblastoma Stem Cells. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4603-4616.	6.4	38
89	Genomic Analyses Reveal Broad Impact of miR-137 on Genes Associated with Malignant Transformation and Neuronal Differentiation in Glioblastoma Cells. <i>PLoS ONE</i> , 2014, 9, e85591.	2.5	38
90	Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling. <i>Neuro-Oncology</i> , 2016, 18, 656-666.	1.2	37

#	ARTICLE	IF	CITATIONS
91	Comparison of Pituitary Adenomas in Elderly and Younger Adults: Clinical Characteristics, Surgical Outcomes, and Prognosis. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1924-1930.	2.6	36
92	The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells. <i>Oncotarget</i> , 2017, 8, 22325-22343.	1.8	36
93	Therapeutic targeting of VEGF in the treatment of glioblastoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 973-984.	3.4	35
94	Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. <i>Neuro-Oncology</i> , 2017, 19, now253.	1.2	35
95	Multi-Kinase Inhibitor C1 Triggers Mitotic Catastrophe of Glioma Stem Cells Mainly through MELK Kinase Inhibition. <i>PLoS ONE</i> , 2014, 9, e92546.	2.5	34
96	Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. <i>Neuro-Oncology</i> , 2015, 17, 1220-1230.	1.2	33
97	MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells. <i>Cell Reports</i> , 2017, 19, 2026-2032.	6.4	33
98	Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27KIP1 and MMP3 expression. <i>Cancer Letters</i> , 2013, 328, 235-242.	7.2	32
99	Developmental expression of glial fibrillary acidic protein mRNA in mouse forebrain germinal zones—implications for stem cell biology. <i>Developmental Brain Research</i> , 2004, 153, 121-125.	1.7	31
100	Phosphoserine Phosphatase Is Expressed in the Neural Stem Cell Niche and Regulates Neural Stem and Progenitor Cell Proliferation. <i>Stem Cells</i> , 2007, 25, 1975-1984.	3.2	31
101	BMPing Off Glioma Stem Cells. <i>Cancer Cell</i> , 2008, 13, 3-4.	16.8	31
102	G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 471, 75-81.	2.1	30
103	A PDGFR $\alpha$ -driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. <i>Nature Communications</i> , 2018, 9, 3116.	12.8	30
104	Methods for Analysis of Brain Tumor Stem Cell and Neural Stem Cell Self-Renewal. <i>Methods in Molecular Biology</i> , 2009, 568, 37-56.	0.9	30
105	Statins affect human glioblastoma and other cancers through TGF- $\beta$ 2 inhibition. <i>Oncotarget</i> , 2019, 10, 1716-1728.	1.8	30
106	Intercellular Cooperation and Competition in Brain Cancers: Lessons From <i>Drosophila</i> and Human Studies. <i>Stem Cells Translational Medicine</i> , 2014, 3, 1262-1268.	3.3	29
107	Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells. <i>Genomics Data</i> , 2015, 5, 333-336.	1.3	29
108	SHP2 regulates proliferation and tumorigenicity of glioma stem cells. <i>Journal of Neuro-Oncology</i> , 2017, 135, 487-496.	2.9	29

#	ARTICLE	IF	CITATIONS
109	Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. <i>Molecular Cancer Research</i> , 2018, 16, 32-46.	3.4	29
110	Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma. <i>Epigenetics</i> , 2018, 13, 432-448.	2.7	29
111	Glioma Stem Cells: Their Role in Chemoresistance. <i>World Neurosurgery</i> , 2012, 77, 237-240.	1.3	27
112	The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. <i>Immunity</i> , 2017, 47, 159-170.e10.	14.3	27
113	5-Aminolevulinic acid-mediated photodynamic therapy can target human glioma stem-like cells refractory to antineoplastic agents. <i>Photodiagnosis and Photodynamic Therapy</i> , 2018, 24, 58-68.	2.6	27
114	Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110 $\alpha$ inhibition. <i>Oncotarget</i> , 2016, 7, 33192-33201.	1.8	26
115	Posttraumatic cerebral infarction in severe traumatic brain injury: characteristics, risk factors and potential mechanisms. <i>Acta Neurochirurgica</i> , 2015, 157, 1697-1704.	1.7	25
116	Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 337-347.	1.2	25
117	Senescence from glioma stem cell differentiation promotes tumor growth. <i>Biochemical and Biophysical Research Communications</i> , 2016, 470, 275-281.	2.1	24
118	Therapeutic potential of targeting glucose metabolism in glioma stem cells. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1233-1236.	3.4	23
119	Targeting glioma-initiating cells via the tyrosine metabolic pathway. <i>Journal of Neurosurgery</i> , 2021, 134, 721-732.	1.6	23
120	A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 39-51.	1.2	22
121	Trifluoromethoxy-benzylated ligands improve amyloid detection in the brain using $^{19}\text{F}$ magnetic resonance imaging. <i>Neuroscience Research</i> , 2009, 63, 76-81.	1.9	21
122	A Precise, Controllable in vitro Model for Diffuse Axonal Injury Through Uniaxial Stretch Injury. <i>Frontiers in Neuroscience</i> , 2019, 13, 1063.	2.8	21
123	Strong therapeutic potential of $\beta$ -secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells. <i>Journal of Neuro-Oncology</i> , 2015, 121, 239-250.	2.9	20
124	Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. <i>Stem Cell Reports</i> , 2017, 9, 1948-1960.	4.8	20
125	$^{67}\text{Zn}$ -Np73/ETS2 complex drives glioblastoma pathogenesis targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 345-356.	1.2	20
126	Ethics of iPSC-Based Clinical Research for Age-Related Macular Degeneration: Patient-Centered Risk-Benefit Analysis. <i>Stem Cell Reviews and Reports</i> , 2014, 10, 743-752.	5.6	18



#	ARTICLE	IF	CITATIONS
127	Sustained NF- $\kappa$ B-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition. <i>Cell Death Discovery</i> , 2019, 5, 72.	4.7	18
128	Obtusaquinone: A Cysteine-Modifying Compound That Targets Keap1 for Degradation. <i>ACS Chemical Biology</i> , 2020, 15, 1445-1454.	3.4	18
129	LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement. <i>Neuro-Oncology</i> , 2020, 22, 1315-1326.	1.2	17
130	Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1134-1147.	4.1	17
131	Combined PI3K-mTOR Targeting of Glioma Stem Cells. <i>Scientific Reports</i> , 2020, 10, 21873.	3.3	17
132	Modulation of Nogo receptor 1 expression orchestrates myelin-associated infiltration of glioblastoma. <i>Brain</i> , 2021, 144, 636-654.	7.6	16
133	Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1415-1422.	4.1	16
134	Cancer Stem Cells in Pediatric Brain Tumors. <i>Current Stem Cell Research and Therapy</i> , 2009, 4, 298-305.	1.3	16
135	Extracellular Vesicles Induce Mesenchymal Transition and Therapeutic Resistance in Glioblastomas through NF- $\kappa$ B/STAT3 Signaling. <i>Advanced Biology</i> , 2020, 4, 1900312.	3.0	15
136	Transcription factors as master regulator for cancer stemness: remove milk from fox?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 873-875.	2.4	13
137	Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor. <i>Journal of Neurosurgery</i> , 2020, 133, 1683-1694.	1.6	13
138	Chloride intracellular channel protein 2 is secreted and inhibits MMP14 activity, while preventing tumor cell invasion and metastasis. <i>Neoplasia</i> , 2021, 23, 754-765.	5.3	12
139	A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells. <i>Oncotarget</i> , 2018, 9, 34379-34397.	1.8	11
140	Solitary metastatic breast carcinoma in a trigeminal nerve mimicking a trigeminal neurinoma. <i>Journal of Neurosurgery</i> , 1996, 85, 677-680.	1.6	8
141	Fluorescence-Guided Brain Tumor Surgery. <i>World Neurosurgery</i> , 2012, 78, 559-564.	1.3	8
142	Proneural mesenchymal transformation of glioma stem cells: do therapies cause evolution of target in glioblastoma?. <i>Future Oncology</i> , 2014, 10, 1527-1530.	2.4	8
143	Tumor edge-to-core transition promotes malignancy in primary-to-recurrent glioblastoma progression in a PLAGL1/CD109-mediated mechanism. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa163.	0.7	8
144	Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens. <i>Journal of Visualized Experiments</i> , 2011, , .	0.3	6

#	ARTICLE	IF	CITATIONS
145	Editorial: glioma subpopulations. <i>Journal of Neurosurgery</i> , 2011, 114, 648-650.	1.6	5
146	Olfactory receptor 5B21 drives breast cancer metastasis. <i>Science</i> , 2021, 24, 103519.	4.1	4
147	Hope and Challenges for Dendritic Cell-Based Vaccine Therapy for Glioblastoma. <i>World Neurosurgery</i> , 2012, 77, 633-635.	1.3	2
148	Engulfing losers by winners in cancer: do cancer stem cells catch eat-me signals from noncancer stem cells?. <i>Future Oncology</i> , 2014, 10, 1335-1338.	2.4	1
149	Abstract 3039: The MELK/FOXM1 axis is a master regulator of proneural to mesenchymal transition (PMT) in glioma stem cells by controlling EZH2 transcriptional activity. , 2014, , .		1
150	Abstract 4839: Targeting glioma stem cells by pharmacologic stabilization of G-quadruplexes. <i>Cancer Research</i> , 2018, 78, 4839-4839.	0.9	1
151	ET-27 * REPLICATION AND SPREAD OF ONCOLYTIC HERPES VIRUS IN GLIOMA STEM CELLS CAN BE ENHANCED BY SPECIFIC INHIBITION OF HISTONE DEACETYLASE 6. <i>Neuro-Oncology</i> , 2014, 16, v85-v85.	1.2	0
152	AI-03 * TARGETING ANGIOGENESIS WITHOUT INCREASING THE STROMAL CELL RESPONSE OR INVASION USING ABT-898, A THROMBOSPONDIN TYPE 1 REPEAT PEPTIDE. <i>Neuro-Oncology</i> , 2014, 16, v1-v1.	1.2	0
153	Abstract 3302: The effects of the g-quadruplex ligand telomestatin to human brain tumor stem cell survival and growth. , 2011, , .		0
154	Abstract 3299: Targeting therapy-resistant glioma cells with novel compounds that inhibit action of survivin. , 2011, , .		0
155	Abstract 4250: A novel thrombospondin-1 mimetic peptide, ABT-898, decreases angiogenesis in a mouse model of glioblastoma multiforme. , 2011, , .		0
156	Abstract 3298: Structure-based computer-aided drug design to discover novel small molecules that target brain tumor stem cells. , 2011, , .		0
157	Abstract LB-103: Signaling via CD44v6 is associated with the growth of CD44-expressing glioma stem-like cells. , 2011, , .		0
158	Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents. <i>Recent Patents on Regenerative Medicine</i> , 2012, 2, 197-207.	0.4	0
159	Abstract 4904: Activation of aldehyde dehydrogenase is essential for growth of mesenchymal glioma stem cells.. , 2013, , .		0
160	Abstract 4912: MELK-dependent phosphorylation of FOXM1 is essential for mitotic progression of glioma stem cells.. , 2013, , .		0
161	Abstract 1941: GSK3 signaling is critical to glioma stem cell growth and survival. , 2014, , .		0
162	Abstract 3877: Evolution of cancer stem cells in glioma to promote their therapy-resistant phenotype. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
163	Abstract 2321: A hematopoietic stem cell factor drives brain tumor initiating cell genesis through Notch signaling. , 2015, , .		0
164	Abstract B26: MAPK-interacting kinase inhibition sensitizes glioblastoma and glioma stem cells to arsenic trioxide. , 2015, , .		0
165	Abstract 2518: Crosstalk between stem and non-stem cells in glioblastoma promotes radioresistance in a CD109-dependent manner. , 2016, , .		0
166	Abstract 695: SHP-2-upregulated ZEB1 is important for PDGFR $\alpha$ -driven glioma epithelial-mesenchymal transition and invasion in mice and humans. , 2016, , .		0
167	Abstract 937: Plasticity in heterogenous cancer stem cells promotes glioblastoma radioresistance. , 2017, , .		0
168	Abstract 869: Mesenchymal identity of breast cancer promotes brain metastases and therapeutic resistance through MLK4/NF $\kappa$ B signaling Pathway. , 2017, , .		0
169	Abstract 4332: Interactome between vascular endothelial cells and Proneural glioma stem cells protects seeds for GBM recurrence from radiation therapy. , 2017, , .		0
170	Abstract 5433: $\beta$ -Tubulin inhibitors reduce GLUT1 membrane trafficking to attenuate tumorigenesis in glioblastoma subtypes. , 2017, , .		0
171	Abstract 1122: MST4 phosphorylation of ATG4B regulates autophagic activity, tumorigenicity, and radio resistance in glioblastoma. , 2018, , .		0
172	Abstract 3432: Novel roles of LY6K in glioblastoma tumorigenesis. , 2019, , .		0
173	CBMS-7 IGF1/N-cadherin/Clusterin signaling axis mediates adaptive radioresistance of glioma stem cells. Neuro-Oncology Advances, 2021, 3, vi3-vi3.	0.7	0